The effects of proteolysis on the human immune mechanism in cancer. A preliminary communication.
D000614:Aminocaproates / Q000494:pharmacology; D000818:Animals; D000912:Antibodies, Neoplasm; D000917:Antibody Formation / Q000187:drug effects; D001201:Ascites / Q000188:drug therapy / Q000473:pathology; D001230:Aspergillus / Q000201:enzymology; D002462:Cell Membrane / Q000187:drug effects; D003168:Complement Fixation Tests; D003601:Cytotoxicity Tests, Immunologic; D004912:Erythrocytes / Q000276:immunology; D005341:Fibrinolysin / Q000037:antagonists & inhibitors; D006801:Humans; D006968:Hypersensitivity, Delayed; D007104:Immune Adherence Reaction; D007111:Immunity, Cellular / Q000187:drug effects*; D066298:In Vitro Techniques; D007938:Leukemia / Q000188:drug therapy* / Q000276:immunology; D008175:Lung Neoplasms / Q000188:drug therapy; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D008545:Melanoma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology*; D010447:Peptide Hydrolases / Q000494:pharmacology* / Q000627:therapeutic use; D010743:Phospholipids; D012756:Sheep / Q000276:immunology; D012882:Skin Tests; D013601:T-Lymphocytes / Q000276:immunology
D000614:Aminocaproates; D000912:Antibodies, Neoplasm; D010743:Phospholipids; D010447:Peptide Hydrolases; D005341:Fibrinolysin